Thangarajah Tanujan, Ling Ferraby K, Lo Ian K
Department of Trauma and Orthopaedic Surgery, University of Calgary, Calgary, Alberta, Canada.
JBJS Essent Surg Tech. 2022 Jan 25;12(1). doi: 10.2106/JBJS.ST.21.00008. eCollection 2022 Jan-Mar.
Over 300,000 rotator cuff repairs are performed annually in the United States, where the annual financial burden of managing shoulder pain has been estimated to be $3 billion. Despite advances in surgical techniques, retear rates range from 39% to 94%. Partial-thickness tears are approximately twice as common as full-thickness tears and can lead to considerable pain and loss of function. Although some partial-thickness tears can be treated nonoperatively, spontaneous healing is unlikely when >50% of the bursal/articular-sided tendon thickness is involved, and thus nonoperative treatment would be unsuccessful. Regeneten (Smith & Nephew) is a bioinductive type-1 collagen implant that can be utilized to repair a partial-thickness rotator cuff tear without formal tendon-bone reattachment. Because this implant does not require tendon-bone reattachment, treatment does not typically entail prolonged rehabilitation. At 2 years postoperatively, this implant has been shown to significantly improve functional outcomes and tendon thickness without any serious adverse events.
A diagnostic arthroscopy is performed via a posterior viewing portal, paying particular attention to the insertion of the posterosuperior rotator cuff onto the humeral head. The subacromial space is entered posteriorly and visualized. With use of electrocautery through a lateral portal, all soft tissue is cleared from the undersurface of the acromion and from the superficial rotator cuff. The coracoacromial ligament is released from the underside of the acromion, and an acromioplasty is performed if indicated. The partial-thickness rotator cuff tear is visualized and examined for tissue quality, tear area, and residual tendon thickness. The size of the tear is measured, and an appropriate implant size is chosen. The lateral portal is enlarged so that the graft can be inserted and unfolded with use of a specialized delivery guide. The implant is centered over the tear, ensuring that it covers as much of the lateral footprint as possible. To complete the procedure, the implant is secured to the tendon with use of soft-tissue staples and to the lateral osseous footprint with use of bone staples.
First-line treatment is often nonoperative and entails activity modification, pharmacological therapies, and targeted physiotherapy directed toward strengthening parascapular muscles and the remaining rotator cuff. Surgical treatment is considered for persistent symptoms. Conventional operative strategies include subacromial decompression, rotator cuff debridement, in situ repair, and conversion to a full-thickness defect and repair.
Partial-thickness tears substantially increase intratendinous strain. This increased strain leads to further tissue degeneration and tear enlargement, likely influencing the high rate of tear propagation observed with nonoperative treatment and nonanatomic operative treatment, such as subacromial decompression. Isolated bioinductive repair of partial-thickness tears with use of a resorbable collagen implant does not involve tendon excision or repair of the tendon to the bone, which can sometimes be challenging. This technique offers a simple solution to a complex problem and has the benefit of an accelerated rehabilitation program compared with formal rotator cuff repair. Accordingly, patient satisfaction with the procedure is high, making this treatment an appealing option.
Short and midterm results following isolated bioinductive repair of partial-thickness tears demonstrate that it is a safe procedure associated with a reduction in pain, increased range of motion, and improvement in functional outcomes. Patients should be counselled regarding the safety of a resorbable collagen patch and its potential to promote healing and improve symptoms.
If the tear is articular, it should be marked with a needle so that the graft can be centered over the tear within the subacromial space.When positioning the implant, ensure that it covers the defect and the lateral footprint.Position the cannulas so that they allow the staples to enter the tissue perpendicular to the tendon and osseous footprint.To prevent tearing of the patch, do not depress the staples with excessive force.
MRI = magnetic resonance imagingPEEK = polyetheretherketoneVAS = visual analogue scaleASES = American Shoulder and Elbow Surgeons Shoulder Score.
在美国,每年进行超过30万例肩袖修复手术,据估计,每年管理肩痛的财政负担达30亿美元。尽管手术技术有所进步,但再撕裂率仍在39%至94%之间。部分厚度撕裂大约是全层厚度撕裂的两倍,可导致相当程度的疼痛和功能丧失。虽然一些部分厚度撕裂可采用非手术治疗,但当滑囊/关节侧肌腱厚度超过50%时,自发愈合的可能性不大,因此非手术治疗可能会失败。Regeneten(施乐辉公司)是一种生物诱导型1型胶原蛋白植入物,可用于修复部分厚度的肩袖撕裂,无需进行正式的肌腱-骨重新附着。由于这种植入物不需要肌腱-骨重新附着,治疗通常不需要长时间的康复。术后2年,已证明这种植入物能显著改善功能结果和肌腱厚度,且无任何严重不良事件。
通过后观察入口进行诊断性关节镜检查,特别注意肩袖后上部分在肱骨头的附着情况。从后方进入肩峰下间隙并进行观察。通过外侧入口使用电灼器,清除肩峰下表面和肩袖浅层的所有软组织。从肩峰下表面松解喙肩韧带,如有指征则进行肩峰成形术。观察部分厚度的肩袖撕裂情况,并检查组织质量、撕裂面积和剩余肌腱厚度。测量撕裂大小,选择合适的植入物尺寸。扩大外侧入口,以便使用专门的输送导向器插入并展开移植物。将植入物置于撕裂中心,确保其尽可能覆盖外侧足迹。为完成手术,使用软组织钉将植入物固定于肌腱,使用骨钉将其固定于外侧骨足迹。
一线治疗通常是非手术治疗,包括改变活动方式、药物治疗以及针对加强肩胛旁肌肉和剩余肩袖的靶向物理治疗。对于持续症状考虑手术治疗。传统手术策略包括肩峰下减压、肩袖清创、原位修复以及转换为全层缺损并进行修复。
部分厚度撕裂会显著增加肌腱内应变。这种增加的应变会导致进一步的组织退变和撕裂扩大,可能影响非手术治疗和非解剖手术治疗(如肩峰下减压)中观察到的高撕裂扩展率。使用可吸收胶原蛋白植入物对部分厚度撕裂进行单独的生物诱导修复不涉及肌腱切除或肌腱与骨的修复,这有时可能具有挑战性。该技术为复杂问题提供了一个简单的解决方案,与正式的肩袖修复相比,具有加速康复计划的优势。因此,患者对该手术的满意度较高,使其成为一个有吸引力的选择。
部分厚度撕裂单独生物诱导修复后的短期和中期结果表明,这是一种安全的手术,可减轻疼痛、增加活动范围并改善功能结果。应向患者咨询可吸收胶原蛋白贴片的安全性及其促进愈合和改善症状的潜力。
如果撕裂是关节侧的,应用针进行标记,以便移植物能在肩峰下间隙内位于撕裂中心。放置植入物时,确保其覆盖缺损和外侧足迹。放置套管时,要使其允许钉子垂直于肌腱和骨足迹进入组织。为防止贴片撕裂,不要用力过大按压钉子。
MRI = 磁共振成像;PEEK = 聚醚醚酮;VAS = 视觉模拟评分;ASES = 美国肩肘外科医师协会肩部评分